Literature DB >> 26503211

Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma.

Huimin An1,2, Yu Zhu1,2, Huyang Xie1,2, Yidong Liu3, Weisi Liu3, Qiang Fu3, Dingwei Ye4,5, Jiejie Xu6,7.   

Abstract

On the basis of aberrant interleukin-8 (IL-8) expression, a crucial angiogenesis factor and potential therapeutic target, in clear-cell renal cell carcinoma (ccRCC), this study aims to assess the prognostic significance of IL-8 in ccRCC. This retrospective study enrolled 271 patients who underwent nephrectomy for ccRCC in a single institution. The associations of IL-8 expression with clinical and pathological features were assessed using chi-squared tests. The impact on cancer-specific survival (CSS) and relapse-free survival (RFS) was analyzed using univariable and multivariable Cox regression models. The area under the receiver operating characteristic (ROC) curve (AUC) was used as an index of prognostic performance. Intratumoral IL-8 was found to be significantly elevated in ccRCC tissues compared with peritumor tissue and be predominately localized in the cytoplasm. Moreover, high IL-8 expression was positively correlated with Fuhrman grade (P < 0.001). Multivariate Cox regression analysis identified IL-8 as an independent adverse prognostic factor of CSS (P < 0.001) and RFS (P < 0.001), which could be incorporated into the traditional TNM staging system to improve the prognostic value for CSS and RFS in ccRCC patients. The predictive accuracy of traditional TNM stage model was significantly improved when IL-8 expression was added. Increased expression of IL-8 is a potential independent adverse prognostic biomarker for CSS and RFS in patients with ccRCC after nephrectomy.

Entities:  

Keywords:  Cancer-specific survival; Clear-cell renal cell carcinoma; Interleukin-8; Prognostic biomarker; Relapse-free survival

Mesh:

Substances:

Year:  2015        PMID: 26503211     DOI: 10.1007/s13277-015-4158-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  28 in total

1.  Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification.

Authors:  M Takahashi; D R Rhodes; K A Furge; H Kanayama ; S Kagawa; B B Haab; B T Teh
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

Review 2.  Toll-like receptors in the induction of the innate immune response.

Authors:  A Aderem; R J Ulevitch
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

3.  The differential expression of proinflammatory cytokines IL-6, IL-8 and TNF-alpha in renal cell carcinoma.

Authors:  B König; F Steinbach; B Janocha; A Drynda; M Stumm; C Philipp; E P Allhoff; W König
Journal:  Anticancer Res       Date:  1999 Mar-Apr       Impact factor: 2.480

4.  Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer.

Authors:  Catherine Murphy; Maryalice McGurk; Johanna Pettigrew; Alfredo Santinelli; Roberta Mazzucchelli; Patrick G Johnston; Rodolfo Montironi; David J J Waugh
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

Review 5.  Interleukin-8 and human cancer biology.

Authors:  K Xie
Journal:  Cytokine Growth Factor Rev       Date:  2001-12       Impact factor: 7.638

6.  Structure and functional expression of a human interleukin-8 receptor.

Authors:  W E Holmes; J Lee; W J Kuang; G C Rice; W I Wood
Journal:  Science       Date:  1991-09-13       Impact factor: 47.728

7.  Genomic heterogeneity of translocation renal cell carcinoma.

Authors:  Gabriel G Malouf; Federico A Monzon; Jérôme Couturier; Vincent Molinié; Bernard Escudier; Philippe Camparo; Xiaoping Su; Hui Yao; Pheroze Tamboli; Dolores Lopez-Terrada; Maria Picken; Marileila Garcia; Asha S Multani; Sen Pathak; Christopher G Wood; Nizar M Tannir
Journal:  Clin Cancer Res       Date:  2013-07-01       Impact factor: 12.531

8.  Signal processing in migrating T24 human bladder carcinoma cells: role of the autocrine interleukin-8 loop.

Authors:  Kerstin Lang; Bernd Niggemann; Kurt S Zanker; Frank Entschladen
Journal:  Int J Cancer       Date:  2002-06-10       Impact factor: 7.396

9.  Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells.

Authors:  Chen Yao; Ying Lin; Mei-Sze Chua; Cai-Sheng Ye; Jiong Bi; Wen Li; Yi-Fan Zhu; Shen-Ming Wang
Journal:  Int J Cancer       Date:  2007-11-01       Impact factor: 7.396

10.  HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.

Authors:  P J Maxwell; R Gallagher; A Seaton; C Wilson; P Scullin; J Pettigrew; I J Stratford; K J Williams; P G Johnston; D J J Waugh
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 9.867

View more
  4 in total

1.  Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis.

Authors:  Y Wang; Y Zhang
Journal:  Clin Transl Oncol       Date:  2019-08-13       Impact factor: 3.405

2.  Overexpression of interleukins IL-17 and IL-8 with poor prognosis in colorectal cancer induces metastasis.

Authors:  Mohsen Mohammadi; Maria Kaghazian; Omid Rahmani; Koorosh Ahmadi; Elham Hatami; Katayoun Ziari; Amir Talebreza
Journal:  Tumour Biol       Date:  2015-12-17

3.  The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma

Authors:  Oktay Halit Aktepe; Gürkan Güner; Deniz Can Güven; Taha Koray Şahin; Fadime Sinem Ardıç; Deniz Yüce; Şuayib Yalçın; Mustafa Erman
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

4.  IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer.

Authors:  Claudia Corrò; Marc E Healy; Stefanie Engler; Bernd Bodenmiller; Zhe Li; Peter Schraml; Achim Weber; Ian J Frew; Markus Rechsteiner; Holger Moch
Journal:  J Pathol       Date:  2019-04-11       Impact factor: 7.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.